



Request for Prior Authorization
HEMATOPOIETICS/CHRONIC ITP

(PLEASE PRINT - ACCURACY IS IMPORTANT)

Form with fields for IA Medicaid Member ID #, Patient name, DOB, Patient address, Provider NPI, Prescriber name, Phone, Prescriber address, Fax, Pharmacy name, Address, Phone, Pharmacy NPI, Pharmacy fax, NDC.

Prior authorization is required for hematopoietics/chronic ITP agents. Request must adhere to all FDA approved labeling. Payment for a non-preferred hematopoietic/chronic ITP agent will be considered following documentation of a recent trial and therapy failure with a preferred hematopoietic/chronic ITP agent, when applicable, unless such a trial would be medically contraindicated. Payment will be considered under the following conditions:

Preferred

Non-Preferred

- Checkboxes for Promacta, Doptelet, Mulpleta, Nplate, Promacta Powder, Tavalisse

Strength Dosage Instructions Quantity Days Supply

\_\_\_\_\_

Thrombocytopenia with Chronic Immune Thrombocytopenia (ITP) (Promacta, Nplate, Tavalisse)

Documentation of an insufficient response to a corticosteroid, immunoglobulin, or splenectomy.

Trial Drug Name: \_\_\_\_\_

Trial start date: \_\_\_\_\_ Trial end date: \_\_\_\_\_

Failure reason: \_\_\_\_\_

Has the patient undergone splenectomy? [ ] No [ ] Yes

Severe Aplastic Anemia (Promacta)

1. Patient has documentation of an insufficient response or intolerance to at least one prior immunosuppressive therapy; and 2. Patient has a platelet count <= 30 x 10^9/L. 3. If criteria for coverage are met, initial authorization will be given for 16 weeks. Documentation of hematologic response after 16 weeks of therapy will be required for further consideration.

Trial Drug Name: \_\_\_\_\_

Trial start date: \_\_\_\_\_ Trial end date: \_\_\_\_\_

Failure reason: \_\_\_\_\_

Platelet count: \_\_\_\_\_ Lab Date: \_\_\_\_\_

Renewal Requests:

Has patient had a hematologic response after 16 weeks of Promacta therapy? [ ] Yes (attach labs) [ ] No



Request for Prior Authorization  
HEMATOPOIETICS/CHRONIC ITP

(PLEASE PRINT – ACCURACY IS IMPORTANT)

**Thrombocytopenia with chronic liver disease in patients scheduled to undergo a procedure (Doptelet, Mulpleta)**

Documentation of the following: 1. Pre-treatment platelet count ; and 2. Scheduled dosing prior to procedure; and 3. Therapy completion prior to scheduled procedure; and 4. Platelet count will be obtained before procedure.

Platelet count: \_\_\_\_\_ Lab Date: \_\_\_\_\_

Date of scheduled procedure: \_\_\_\_\_

Date for start of drug treatment: \_\_\_\_\_

After the last dose, a platelet count will be obtained prior to undergoing the procedure:  Yes  No

**Other Diagnosis:** \_\_\_\_\_

Reason for use of Non-Preferred drug requiring prior approval: \_\_\_\_\_

Other medical conditions to consider: \_\_\_\_\_

**Attach lab results and other documentation as necessary.**

Prescriber signature (Must match prescriber listed above.)	Date of submission
--	--------------------

**IMPORTANT NOTE:** In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.